Omalizumab Biosimilars Market Share Expands Amid Rising Demand for Cost-Effective Allergy Treatments | Valuates Reports

Omalizumab Biosimilars Market
The global market for Omalizumab Biosimilars was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-26N9928/Global_Omalizumab_Biosimilars_Market_Research_Report_2022

The omalizumab biosimilars market is witnessing significant growth, driven by the increasing prevalence of allergic conditions and the need for more affordable therapeutic options. As healthcare systems worldwide seek cost-effective solutions, biosimilars of omalizumab are emerging as viable alternatives to the original biologic, offering similar efficacy and safety profiles.

Key Market Drivers
The rising incidence of conditions such as severe persistent allergic asthma, chronic spontaneous urticaria, and nasal polyps has led to heightened demand for effective treatments. Omalizumab, a monoclonal antibody targeting immunoglobulin E (IgE), has been instrumental in managing these conditions. The introduction of biosimilars provides a more accessible option for patients and healthcare providers, potentially reducing treatment costs and expanding patient access.

Regulatory Approvals and Market Entry
Recent regulatory approvals have bolstered the market's growth trajectory. For instance, Omlyclo, a biosimilar of omalizumab developed by Celltrion Healthcare, received approval for medical use in the European Union in May 2024 and in the United States in March 2025. These approvals signify a growing acceptance of biosimilars in major markets, paving the way for increased adoption and competition.

Regional Insights
The Asia-Pacific region is poised for substantial growth in the omalizumab biosimilars market, attributed to the rising prevalence of allergic diseases and increasing healthcare expenditures. North America and Europe continue to be significant markets, supported by established healthcare infrastructures and a growing emphasis on cost containment in biologic therapies.

Industry Outlook
The omalizumab biosimilars market is expected to maintain its upward momentum, fueled by the ongoing need for affordable allergy treatments and the expanding pipeline of biosimilar candidates. As more biosimilars enter the market, competition is likely to intensify, potentially leading to further price reductions and increased accessibility for patients.

Valuates Reports anticipates sustained growth in the omalizumab biosimilars market, driven by the convergence of clinical demand, regulatory support, and the imperative for cost-effective healthcare solutions.

Segment by Type

• 150 mg/mL
• 75 mg/0.5 mL

Segment by Application

• Persistent Asthma
• Nasal Polyps
• Chronic Idiopathic Urticaria

By Company

Roche, Novartis, Glenmark Pharmaceuticals, Selexis, Generium, CuraTeQ, Celltrion Healthcare, Alvotech, BiosanaPharma, Mabpharm, CSPC Pharmaceutical Group, Biomabs, HisunPharm

View full report
https://reports.valuates.com/market-reports/QYRE-Auto-26N9928/global-omalizumab-biosimilars

Valuates,
4th Floor,
Balaraj's Arcade,
Whitefield Main road,
Bangalore 560066,

Valuates offers an extensive collection of market research reports that helps companies to take intelligent strategical decisions based on current and forecasted Market trends.

This release was published on openPR.